Claudia Goettsch1, Joshua D Hutcheson1, Sumihiko Hagita1, Maximillian A Rogers1, Michael D Creager1, Tan Pham1, Jung Choi1, Andrew K Mlynarchik1, Brett Pieper1, Mads Kjolby2, Masanori Aikawa3, Elena Aikawa4. 1. Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. 2. The Lundbeck Foundation Research Center MIND, Danish Research Institute of Translational Neuroscience, Nordic EMBL Partnership for Molecular Medicine, Danish Diabetes Academy, Department of Biomedicine, Aarhus University, 8000, Denmark. 3. Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Center for Excellence in Vascular Biology, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. 4. Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Center for Excellence in Vascular Biology, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: eaikawa@partners.org.
Abstract
BACKGROUND AND AIMS: Studying atherosclerotic calcification in vivo requires mouse models with genetic modifications. Previous studies showed that injection of recombinant adeno-associated virus vector (AAV) encoding a gain-of-function mutant PCSK9 into mice promotes atherosclerosis. We aimed to study cardiovascular calcification induced by PCSK9 AAV in C57BL/6J mice. METHODS: 10 week-old C57BL/6J mice received a single injection of AAV encoding mutant mPCSK9 (rAAV8/D377Y-mPCSK9). Ldlr(-/-) mice served as positive controls. Mice consumed a high-fat, high-cholesterol diet for 15 or 20 weeks. Aortic calcification was assessed by fluorescence reflectance imaging (FRI) of a near-infrared calcium tracer. RESULTS: Serum levels of PCSK9 (0.14 μg/mL to 20 μg/mL, p < 0.01) and total cholesterol (82 mg/dL to 820 mg/dL, p < 0.01) increased within one week after injection and remained elevated for 20 weeks. Atherosclerotic lesion size was similar between PCSK9 AAV and Ldlr(-/-) mice. Aortic calcification was 0.01% ± 0.01 in PCSK9 AAV mice and 15.3% ± 6.1 in Ldlr(-/-) mice at 15 weeks (p < 0.01); by 20 weeks, the PCSK9 AAV mice aortic calcification grew to 12.4% ± 4.9. Tissue non-specific alkaline phosphatase activity was similar in PCSK9 AAV mice and Ldlr(-/-) mice at 15 and 20 weeks, respectively. As example of the utility of this model in testing modulators of calcification in vivo, PCSK9 AAV injection to sortilin-deficient mice demonstrated reduced aortic calcification by 46.3% (p < 0.05) compared to littermate controls. CONCLUSIONS: A single injection of gain-of-function PCSK9 AAV into C57BL/6J mice is a useful tool to study cardiovascular calcification in mice with no genetic manipulation.
BACKGROUND AND AIMS: Studying atherosclerotic calcification in vivo requires mouse models with genetic modifications. Previous studies showed that injection of recombinant adeno-associated virus vector (AAV) encoding a gain-of-function mutant PCSK9 into mice promotes atherosclerosis. We aimed to study cardiovascular calcification induced by PCSK9 AAV in C57BL/6J mice. METHODS: 10 week-old C57BL/6J mice received a single injection of AAV encoding mutant mPCSK9 (rAAV8/D377Y-mPCSK9). Ldlr(-/-) mice served as positive controls. Mice consumed a high-fat, high-cholesterol diet for 15 or 20 weeks. Aortic calcification was assessed by fluorescence reflectance imaging (FRI) of a near-infrared calcium tracer. RESULTS: Serum levels of PCSK9 (0.14 μg/mL to 20 μg/mL, p < 0.01) and total cholesterol (82 mg/dL to 820 mg/dL, p < 0.01) increased within one week after injection and remained elevated for 20 weeks. Atherosclerotic lesion size was similar between PCSK9 AAV and Ldlr(-/-) mice. Aortic calcification was 0.01% ± 0.01 in PCSK9 AAV mice and 15.3% ± 6.1 in Ldlr(-/-) mice at 15 weeks (p < 0.01); by 20 weeks, the PCSK9 AAV miceaortic calcification grew to 12.4% ± 4.9. Tissue non-specific alkaline phosphatase activity was similar in PCSK9 AAV mice and Ldlr(-/-) mice at 15 and 20 weeks, respectively. As example of the utility of this model in testing modulators of calcification in vivo, PCSK9 AAV injection to sortilin-deficient mice demonstrated reduced aortic calcification by 46.3% (p < 0.05) compared to littermate controls. CONCLUSIONS: A single injection of gain-of-function PCSK9 AAV into C57BL/6J mice is a useful tool to study cardiovascular calcification in mice with no genetic manipulation.
Authors: Marta Roche-Molina; David Sanz-Rosa; Francisco M Cruz; Jaime García-Prieto; Sergio López; Rocío Abia; Francisco J G Muriana; Valentín Fuster; Borja Ibáñez; Juan A Bernal Journal: Arterioscler Thromb Vasc Biol Date: 2014-10-23 Impact factor: 8.311
Authors: Zuhier Awan; Maxime Denis; Dana Bailey; Adel Giaid; Annik Prat; David Goltzman; Nabil G Seidah; Jacques Genest Journal: Atherosclerosis Date: 2011-08-26 Impact factor: 5.162
Authors: Martin Maeng Bjørklund; Anne Kruse Hollensen; Mette Kallestrup Hagensen; Frederik Dagnaes-Hansen; Christina Christoffersen; Jacob Giehm Mikkelsen; Jacob Fog Bentzon Journal: Circ Res Date: 2014-03-27 Impact factor: 17.367
Authors: Rozh H Al-Mashhadi; Martin M Bjørklund; Martin B Mortensen; Christina Christoffersen; Torben Larsen; Erling Falk; Jacob F Bentzon Journal: Diabetologia Date: 2015-05-31 Impact factor: 10.122
Authors: Elena Aikawa; Peter Whittaker; Mark Farber; Karen Mendelson; Robert F Padera; Masanori Aikawa; Frederick J Schoen Journal: Circulation Date: 2006-03-14 Impact factor: 29.690
Authors: Nikhil V Joshi; Alex T Vesey; Michelle C Williams; Anoop S V Shah; Patrick A Calvert; Felicity H M Craighead; Su Ern Yeoh; William Wallace; Donald Salter; Alison M Fletcher; Edwin J R van Beek; Andrew D Flapan; Neal G Uren; Miles W H Behan; Nicholas L M Cruden; Nicholas L Mills; Keith A A Fox; James H F Rudd; Marc R Dweck; David E Newby Journal: Lancet Date: 2013-11-11 Impact factor: 79.321
Authors: Kelsey E Jarrett; Ciaran Lee; Marco De Giorgi; Ayrea Hurley; Baiba K Gillard; Alexandria M Doerfler; Ang Li; Henry J Pownall; Gang Bao; William R Lagor Journal: Arterioscler Thromb Vasc Biol Date: 2018-09 Impact factor: 8.311
Authors: Natalia V Mushenkova; Volha I Summerhill; Yulia Yu Silaeva; Alexey V Deykin; Alexander N Orekhov Journal: Am J Transl Res Date: 2019-08-15 Impact factor: 4.060
Authors: Aimee E Vozenilek; Cassidy M R Blackburn; Robert M Schilke; Sunitha Chandran; Reneau Castore; Ronald L Klein; Matthew D Woolard Journal: Atherosclerosis Date: 2018-09-08 Impact factor: 5.162
Authors: Liwei Ren; Yuan Sun; Hong Lu; Dien Ye; Lijuan Han; Na Wang; Alan Daugherty; Furong Li; Miaomiao Wang; Fengting Su; Wenjun Tao; Jie Sun; Noam Zelcer; Adam E Mullick; A H Jan Danser; Yizhou Jiang; Yongcheng He; Xiongzhong Ruan; Xifeng Lu Journal: Circ Res Date: 2018-01-04 Impact factor: 17.367